Vai al contenuto principale della pagina
Autore: | Denora Nunzio |
Titolo: | Paediatric Formulation: Design and Development |
Pubblicazione: | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
Descrizione fisica: | 1 electronic resource (205 p.) |
Soggetto topico: | Medicine |
Soggetto non controllato: | dasatinib |
Duchenne muscular dystrophy | |
cyclodextrin inclusion complex | |
phase solubility studies | |
paediatric age | |
liquid formulation | |
tumorspheres | |
retinoblastoma | |
topotecan | |
penetration | |
confocal microscopy | |
poorly water soluble drug | |
solubility enhancement | |
grinding | |
spray congealing | |
neglected tropical diseases | |
polymorph | |
Norvir® | |
ritonavir | |
poorly soluble compound | |
pediatric | |
palatability assessment | |
bioavailability | |
flavor profile | |
Interleukin-1 | |
anakinra | |
canakinumab | |
innovative biotechnologies | |
autoinflammatory disease | |
Kawasaki disease | |
systemic juvenile idiopathic arthritis | |
personalized medicine | |
child | |
pediatrics | |
neonates | |
formulation | |
product development | |
formulation development | |
oral | |
parenteral | |
topical | |
inhaled | |
intra nasal | |
biopharmaceutics | |
administration | |
excipient | |
NICU | |
device | |
medication error | |
dosage form | |
modified release | |
drug delivery | |
paediatric formulation development | |
paediatric dosage forms | |
chronic myeloid leukemia | |
tyrosine kinase inhibitors | |
pediatric age | |
imatinib | |
nilotinb | |
ponatinib | |
Orodispersible formulation | |
pyrazinamide | |
pediatric drug delivery | |
tuberculosis | |
design of experiments | |
children | |
edible films | |
development | |
design | |
paediatric | |
age-related | |
palatable | |
taste-masking | |
acceptable | |
Persona (resp. second.): | LopalcoAntonio |
DenoraNunzio | |
Sommario/riassunto: | The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. |
Altri titoli varianti: | Paediatric Formulation |
Titolo autorizzato: | Paediatric Formulation: Design and Development |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910557304003321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |